✦ LIBER ✦

Management of Dyslipidemia Associated With Protease Inhibitors

✍ Scribed by John R. Kapoor

Book ID: 113445323
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 97 KB
Volume: 103
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2008.10.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term cardiovascular risk with prote

Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia

✍ William B. Kannel; Michael Giordano 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Lipodystrophy associated with protease i

Lipodystrophy associated with protease inhibitors

✍ I. Panse; E. Vasseur; M.L. Raffin-Sanson; F. Staroz; E. Rouveix; P. Saiag 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

## Abstract Lipodystrophies, characterized by reduction of subcutaneous fat over part or all of the body surface, are uncommon. Their causes are unknown. Recently, lipodystrophy has been reported in human immunodeficiency virus (HIV)-infected patients taking protease inhibitors, which have been rec

Dyslipidemia in the era of HIV protease

Dyslipidemia in the era of HIV protease inhibitors

✍ James H Stein 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Lipid Abnormalities Associated With Prot

Lipid Abnormalities Associated With Protease Inhibitors

✍ N. Holly Melroe; Jessica Kopaczewski; Keith Henry; Jacquelyn Huebsch 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Galactorrhoea and hyperprolactinaemia as

Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors

✍ Jane Hutchinson; Maurice Murphy; Rachel Harries; Celia J Skinner 📂 Article 📅 2000 🏛 The Lancet 🌐 English ⚖ 54 KB

Intervention for Hyperlipidemia Associat

Intervention for Hyperlipidemia Associated With Protease Inhibitors

✍ N. Holly Melroe; Jessica Kopaczewski; Keith Henry; Jacquelyn Huebsch 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 86 KB